Order Article Reprints

Baertsch M-A, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, Müller-Tidow C, Goldschmidt H, Raab M-S, Hillengass J, et al. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers. 2021; 13(18):4706. https://doi.org/10.3390/cancers13184706

Baertsch, Marc-Andrea, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, and et al. 2021. "Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma" Cancers 13, no. 18: 4706. https://doi.org/10.3390/cancers13184706

Baertsch, M. -A., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., Müller-Tidow, C., Goldschmidt, H., Raab, M. -S., Hillengass, J., & Giesen, N. (2021). Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 13(18), 4706. https://doi.org/10.3390/cancers13184706